NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and XWELL (NASDAQ:XWEL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Institutional & Insider Ownership
16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 8.7% of XWELL shares are owned by institutional investors. 8.9% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 13.9% of XWELL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
NeuroOne Medical Technologies has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, XWELL has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $3.45 million | 11.37 | -$12.32 million | ($0.15) | -5.23 |
| XWELL | $33.90 million | 0.19 | -$16.85 million | ($4.10) | -0.27 |
NeuroOne Medical Technologies has higher earnings, but lower revenue than XWELL. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than XWELL, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NeuroOne Medical Technologies and XWELL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -55.44% | -163.49% | -78.67% |
| XWELL | -63.18% | -265.41% | -72.67% |
Analyst Ratings
This is a summary of current ratings and target prices for NeuroOne Medical Technologies and XWELL, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 0 | 0 | 1 | 0 | 3.00 |
| XWELL | 0 | 0 | 0 | 0 | 0.00 |
NeuroOne Medical Technologies presently has a consensus price target of $1.45, indicating a potential upside of 84.81%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher probable upside, research analysts plainly believe NeuroOne Medical Technologies is more favorable than XWELL.
Summary
NeuroOne Medical Technologies beats XWELL on 9 of the 14 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
About XWELL
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
